EAGLE PHARMACEUTICALS, INC. Cashflow Statement

Ask AI

Overview Financial Statements SEC Filings Executives News Red Flags Capital Raising Ownership Insider Transactions Congressional Trades

Financial Statements

Income Statement Balance Sheet Cashflow Statement

Consolidated Statements of Cash Flows

In millions of USD, except per-share amounts

	FY2022 12 months to Dec 31, 2022	FY2021 12 months to Dec 31, 2021	FY2020 12 months to Dec 31, 2020	FY2019 12 months to Dec 31, 2019	FY2018 12 months to Dec 31, 2018
Cash flows from operating activities:
Net income (loss)
Adjustments to reconcile net income (loss) to net cash provided by operating activities:
Deferred income taxes
Depreciation expense
Noncash operating lease expense related to right-of-use assets
Amortization expense of intangible assets
Convertible promissory note related credit losses
Stock-based compensation expense
Change in fair value of contingent consideration
Fair value adjustments on equity investment
Amortization of debt issuance costs
Gain on sale of asset
Fair value adjustments on settled accelerated share repurchase agreement
Asset impairment charge
Non-cash restructuring charge
Fair value adjustments related to derivative instrument
Gain on fair value adjustments related to debt
Accretion of discount on convertible promissory note
Loss on write-off of promissory note
Changes in operating assets and liabilities which provided (used) cash:
Accounts receivable
Inventories
Prepaid expenses and other current assets
Accounts payable
Deferred revenue
Accrued expenses and other liabilities
Other assets and other long-term liabilities, net

Net cash provided by operating activities
Cash flows from investing activities:
Purchase of Acacia, net of cash acquired
Proceeds from sale of diclofenac-misoprostol
Purchase of equity investment security
Purchase of property and equipment
Purchase of short term investments
Maturities of short term investments
Payment for Docetaxel acquisition
Purchase of convertible promissory note
Net cash used in investing activities

Cash flows from financing activities:
Repurchases of common stock
Payment of contingent consideration
Proceeds from existing revolving credit facility
Repayment of existing revolving credit facility
Debt proceeds
Payment of debt
Payment of debt financing costs
Payment of employee withholding tax upon vesting of stock-based awards
Payments for employee net option exercises
Proceeds from common stock option exercises
Net cash used in financing activities
Net (decrease) increase in cash and cash equivalents
Net decrease in cash and cash equivalents
Cash and cash equivalents at beginning of period
Cash and cash equivalents at end of period
Supplemental disclosures of cash flow information:
Cash paid during the period for:
Income taxes, net
Interest

Value of common stock issued for the Eagle Biologics acquisition
Contingent consideration - business acquisitions
Interest
Right-of-use asset obtained in exchange for lease obligation, inclusive of a lease amendment

Comments